Ligand Pharmaceuticals | LGND - Current Assets


Ligand Pharmaceuticals reported $865.42M in Current Assets for its fiscal quarter ending in March of 2026.





Current Assets Change Date
Agenus USD 95.28M 38.15M Mar/2026
Amgen USD 31.48B 2.42B Mar/2026
Anika Therapeutics USD 93.56M 9.8M Mar/2026
Arrowhead Research USD 1.84B 665.36M Mar/2026
Baxter International USD 6.85B 25M Mar/2026
Bristol-Myers Squibb USD 27.21B 2.18B Mar/2026
Eli Lilly USD 54.84B 794M Mar/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Enviri Corporation USD 722.11M 1.43M Mar/2026
Gilead Sciences USD 18.64B 1.25B Mar/2026
GlaxoSmithKline GBP 17.76B 251M Mar/2026
Glaxosmithkline GBP 23.59B 390.44M Dec/2025
Heron Therapeutics USD 228.98M 9.08M Mar/2026
Insmed USD 1.61B 181.04M Mar/2026
Intrexon USD 23.72M 45.04M Jun/2024
Ionis Pharmaceuticals USD 2.94B 52M Mar/2026
Karyopharm Therapeutics USD 103.15M 13.4M Dec/2025
Ligand Pharmaceuticals USD 865.42M 33.14M Mar/2026
MacroGenics USD 182.52M 37.42M Mar/2026
Merck USD 35.02B 8.5B Mar/2026
Pacira USD 514.96M 33.01M Mar/2026
Pfizer USD 42.82B 76M Mar/2026
Rigel Pharmaceuticals USD 214.93M 39.53M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Veracyte USD 522.17M 33.8M Mar/2026